Tounian P - Search Results

1

Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.

Peretti N, Vimont A, Mas E, Lemale J, Reynaud R, Tounian P, Poinsot P, Restier L, Paillard F, Pradignac A, Pucheu Y, Rabès JP, Bruckert E, Gallo A, Béliard S. Peretti N, et al. Among authors: tounian p. Arch Pediatr. 2024 Apr;31(3):188-194. doi: 10.1016/j.arcped.2024.01.004. Epub 2024 Mar 27. Arch Pediatr. 2024. PMID: 38538465 Free article.

2

The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.

Béliard S, Millier A, Carreau V, Carrié A, Moulin P, Fredenrich A, Farnier M, Luc G, Rosenbaum D, Toumi M, Bruckert E; French FH Registry group. Béliard S, et al. J Clin Lipidol. 2016 Sep-Oct;10(5):1129-1136.e3. doi: 10.1016/j.jacl.2016.06.007. Epub 2016 Jun 27. J Clin Lipidol. 2016. PMID: 27678429

3

[Let's stop proton pump inhibitor prescriptions for suspected GERD in non-validated indications!].

Mouterde O, Chouraqui JP, Ruemmele F, Mas E, Bellaïche M; Groupe francophone d’hépatologie, gastroentérologie et nutrition pédiatriques; Comité de relecture du manuscrit; Faure C, Gottrand F, Tounian P. Mouterde O, et al. Among authors: tounian p. Arch Pediatr. 2014 Jul;21(7):686-9. doi: 10.1016/j.arcped.2014.04.030. Epub 2014 Jun 14. Arch Pediatr. 2014. PMID: 24938917 French. No abstract available.

4

Hyperphagia and impulsivity: use of self-administered Dykens' and in-house impulsivity questionnaires to characterize eating behaviors in children with severe and early-onset obesity.

Arnouk L, Chantereau H, Courbage S, Tounian P, Clément K, Poitou C, Dubern B. Arnouk L, et al. Among authors: tounian p. Orphanet J Rare Dis. 2024 Feb 23;19(1):84. doi: 10.1186/s13023-024-03085-1. Orphanet J Rare Dis. 2024. PMID: 38395939 Free PMC article.

5

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group. Beaugerie L, et al. Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7. Lancet. 2009. PMID: 19837455

6

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group. Sokol H, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23. Inflamm Bowel Dis. 2012. PMID: 22271569

7

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group. Beaugerie L, et al. Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25. Gut. 2014. PMID: 24162591

8

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.

Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M; Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France Study Group. Beaugerie L, et al. Clin Gastroenterol Hepatol. 2018 Jun;16(6):892-899.e2. doi: 10.1016/j.cgh.2017.11.041. Epub 2017 Dec 2. Clin Gastroenterol Hepatol. 2018. PMID: 29199142

9

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group. Bourrier A, et al. Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9. Aliment Pharmacol Ther. 2016. PMID: 26549003 Free article.

10

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25. Gastroenterology. 2011. PMID: 21708105

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page